



Lamark Biotech Raises ₹6.5 Crore in Pre-Series A Round Led by IAN Group, Powered by BioAngels

JULY 1, 2025  BY IAN-ADMIN  1 LIKE  0 COMMENTS

Funding to accelerate the development of thermostable insulin and expand biological access

New Delhi, India, 1st July 2025: Lamark Biotech, an innovation-led biopharma startup, has successfully raised a Pre-Series A round led by IAN Group (including IAN Alpha Fund, powered by BioAngels) of ₹6.5 Crore, led by Dr. Vinayender Tulla, Dr. Nita Roy, and Mr. Venkataraman KNK.

Founded in 2018 by Dr. Vaibhav Bhatia, an entrepreneur and Biochemist by training, Lamark Biotech is focused on reimagining drug delivery for chronic and life-altering diseases. Its proprietary Pro

cold chain dependency.

Vaibhav Bhatia, Founder and CEO of Lamark Biotech, said, *“This funding round is a key milestone for Lamark, but also for the patients across the planet. We’re accelerating our program and expanding ProteoStrong™ to more critical therapeutics using this resource to make safe and high-efficacy biologics for all. We believe, ‘if it is not accessible, it must be made.’”*

Padmaja Ruparel, Co-founder, IAN Group, said, *“Investment in Lamark represents a commitment to invest and grow innovations that solve real problems. The solution is critical in low-resource settings with Lamark’s thermostable biologics which can make critical treatments accessible to billions of people, both in India and globally.”*

The Ahmedabad-headquartered startup, leveraging R&D base of Venture Center, Pune, is advancing a new class of temperature-resilient biologics that retain potency under ambient conditions, ideal for underserved regions where cold storage infrastructure is limited.

With its lead program, InsulinStrong, Lamark is targeting the ₹4,000 crore Indian market and plans to expand across Southeast Asia and the UAE. expanding its platform into diabetic complications and immunotherapy. In the next 24 months, it plans to file new international patents, build partnerships with pharma companies, CDMOs, and global health agencies.

Amid growing global efforts to enhance healthcare access and strengthen drug development, Lamark Biotech is strategically positioned to lead the next generation of biopharmaceuticals with robust, cold-chain-independent solutions.

About Lamark Biotech:

Lamark Biotech is an innovation-driven biopharmaceutical startup focused on developing novel formulations of biologics for chronic and life-altering diseases. The company’s core mission is to simplify complex therapeutic proteins and peptides to improve their shelf-life, efficacy, and stability. With a strong emphasis on global healthcare, it addresses critical gaps in formulation technology.



About IAN Group:

IAN Group is the country's single largest platform for seed and early-stage investment. IAN Angel Network, BioAngels and IAN Fund I and IAN Alpha Fund enabling entrepreneurs to raise lakhs to Rs. 50 crores. The platform brings money, mentoring from successful entrepreneurs and market access. The platform is sector-agnostic and has funded innovative start-ups across India and 7 other countries, thereby growing the global footprint of companies. IAN has been a part of iconic business and economic events of Independent India, over 75 years along with Naukri.com amongst others.

FUNDING ANNOUNCEMENTS

Always stay up-to-date.

Join Our Newsletter

IAN

- » [About Us](#)
- » [Team](#)
- » [Join IAN Angel Fund](#)
- » [Join IAN Alpha Fund](#)

Quick Links

- » [Events](#)
- » [Submit Plan](#)
- » [Privacy Policy](#)
- » [Terms & Conditions](#)

Resources

- » [IAN Insights](#)
- » [News & Media](#)
- » [Blog](#)

Disclaimer : IANPL acts as an introducer between the investor and start-up companies to enable the start-up companies get the required funding. IANPL is a distinct and separate from a Stock Exchange which is set up under the provisions of Securities Contract Regulation Act, 1956. IANPL does not guarantee the success of investments.